245 related articles for article (PubMed ID: 32643492)
1. Efficacy and safety of peficitinib in rheumatoid arthritis.
Kaneko Y
Mod Rheumatol; 2020 Sep; 30(5):773-778. PubMed ID: 32643492
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Iwasaki M; Katayama K; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Shiomi T; Yamada E; van der Heijde D
Ann Rheum Dis; 2019 Oct; 78(10):1305-1319. PubMed ID: 31350269
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Song YW; Chen YH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Nakashima Y; Shiomi T; Yamada E
Arthritis Res Ther; 2020 Mar; 22(1):47. PubMed ID: 32164762
[TBL] [Abstract][Full Text] [Related]
5. Peficitinib: First Global Approval.
Markham A; Keam SJ
Drugs; 2019 Jun; 79(8):887-891. PubMed ID: 31093950
[TBL] [Abstract][Full Text] [Related]
6. Peficitinib for the treatment of rheumatoid arthritis: an overview from clinical trials.
Tanaka Y; Izutsu H
Expert Opin Pharmacother; 2020 Jun; 21(9):1015-1025. PubMed ID: 32345068
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.
Takeuchi T; Tanaka Y; Iwasaki M; Ishikura H; Saeki S; Kaneko Y
Ann Rheum Dis; 2016 Jun; 75(6):1057-64. PubMed ID: 26672064
[TBL] [Abstract][Full Text] [Related]
8. A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years.
Takeuchi T; Tanaka Y; Rokuda M; Izutsu H; Kaneko Y; Fukuda M; Kato D
Mod Rheumatol; 2021 May; 31(3):543-555. PubMed ID: 33050760
[TBL] [Abstract][Full Text] [Related]
9. Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.
Genovese MC; Greenwald M; Codding C; Zubrzycka-Sienkiewicz A; Kivitz AJ; Wang A; Shay K; Wang X; Garg JP; Cardiel MH
Arthritis Rheumatol; 2017 May; 69(5):932-942. PubMed ID: 28118538
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of tofacitinib and peficitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Int J Rheum Dis; 2020 Jul; 23(7):868-875. PubMed ID: 32483919
[TBL] [Abstract][Full Text] [Related]
11. Peficitinib hydrobromide to treat rheumatoid arthritis.
Gutiérrez-Ureña SR; Amaya-Cabrera EL; Uribe-Martínez JF; Ventura-Valenzuela ME; Rosal-Arteaga C; Martínez-Bonilla GE; González-Díaz V; Almengor-Montenegro O; Cerpa-Cruz S
Drugs Today (Barc); 2020 Aug; 56(8):505-514. PubMed ID: 33025946
[TBL] [Abstract][Full Text] [Related]
12. Peficitinib, a JAK Inhibitor, in the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate.
Kivitz AJ; Gutierrez-Ureña SR; Poiley J; Genovese MC; Kristy R; Shay K; Wang X; Garg JP; Zubrzycka-Sienkiewicz A
Arthritis Rheumatol; 2017 Apr; 69(4):709-719. PubMed ID: 27748083
[TBL] [Abstract][Full Text] [Related]
13. JAK3-selective inhibitor peficitinib for the treatment of rheumatoid arthritis.
Qiu Q; Feng Q; Tan X; Guo M
Expert Rev Clin Pharmacol; 2019 Jun; 12(6):547-554. PubMed ID: 31059310
[No Abstract] [Full Text] [Related]
14. JAK inhibitors for the treatment of rheumatoid arthritis.
Morinobu A
Immunol Med; 2020 Dec; 43(4):148-155. PubMed ID: 32501149
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
16. Impact of age on the efficacy and safety of peficitinib (ASP015K) for the treatment of rheumatoid arthritis.
Tanaka Y; Takeuchi T; Kato D; Kaneko Y; Fukuda M; Miyatake D
Mod Rheumatol; 2022 Jul; 32(4):696-707. PubMed ID: 34850095
[TBL] [Abstract][Full Text] [Related]
17. Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis.
Zhu T; Moy S; Valluri U; Cao Y; Zhang W; Sawamoto T; Chindalore V; Akinlade B
Clin Drug Investig; 2020 Sep; 40(9):827-838. PubMed ID: 32591978
[TBL] [Abstract][Full Text] [Related]
18. A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years.
Tanaka Y; Takeuchi T; Kato D; Kaneko Y; Fukuda M; Izutsu H; Rokuda M
Mod Rheumatol; 2022 Jul; 32(4):708-717. PubMed ID: 34918131
[TBL] [Abstract][Full Text] [Related]
19. Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Lee YH; Song GG
Clin Drug Investig; 2020 Jan; 40(1):65-72. PubMed ID: 31602572
[TBL] [Abstract][Full Text] [Related]
20. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model.
Ito M; Yamazaki S; Yamagami K; Kuno M; Morita Y; Okuma K; Nakamura K; Chida N; Inami M; Inoue T; Shirakami S; Higashi Y
J Pharmacol Sci; 2017 Jan; 133(1):25-33. PubMed ID: 28117214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
